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Cannabis sativa L. contains more than 100 phytocannabinoids that can interact with cannabinoid receptors CB1 and CB2. 
None of the cannabinoid receptor ligands is entirely CB1- or CB2-specific. The effects of cannabinoids therefore differ 
not just because of different potency at cannabinoid receptors but also because they can interact with other non-CB1 and 
non-CB2 targets, such as TRPV1, GPR55, and GPR119. The most studied phytocannabinoid is Δ
9-tetrahydrocannabinol 
(THC). THC is a partial agonist at both cannabinoid receptors, but its psychotomimetic effect is produced primarily via 
activation of the CB1 receptor, which is strongly expressed in the central nervous system, with the noteworthy exception 
of the brain stem. Although acute cognitive and other effects of THC are well known, the risk of irreversible 
neuropsychological effects of THC needs further research to elucidate the association. Unlike THC, phytocannabinoid 
cannabidiol (CBD) does not appear to have psychotomimetic effects but may interact with some of the effects of THC if 
taken concomitantly. CBD administered orally has recently undergone well-controlled clinical trials to assess its safety 
in the treatment of paediatric epilepsy syndromes. Their findings point to increased transaminase levels as a safety issue 
that calls for postmarketing surveillance for liver toxicity. The aim of this review is to summarise what is known about 
acute and chronic toxicological effects of both compounds and address the gaps in knowledge about the safety of exogenous 
cannabinoids that are still open.
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With the growing interest in the use of cannabinoids for 
medicinal purposes grows a need for a systematic review 
of their toxicological properties. There are still many 
uncertainties and contradictions remaining from the 
increasing number of published cannabinoid safety studies. 
This is because these studies vary to extremes in their 
methodology and quality, rendering results difficult to 
compare. Moreover, toxicity is not systematically covered, 
and there are no chronic toxicity data from well-defined 
exposure settings. Higher quality toxicological data are 
available for cannabinoid-based medicines that are 
manufactured today as approved drugs. However, the main 
indications for their use are serious and/or rare diseases, 
mostly after all other treatment has failed, so their 
toxicological profile is less detailed than that of the drugs 
of first choice (1).
Cannabinoid receptor ligands are a varied group of over 
100 chemical compounds isolated from Cannabis sativa L. 
(2). The best-characterised cannabinoids found in the 
cannabis plant are Δ9-tetrahydrocannabinol (THC) and 
cannabidiol (CBD). They can interact with two types of 
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cannabinoid receptors – cannabinoid type 1 (CB1) and 
cannabinoid type 2 (CB2) – that both belonging to the 
superfamily of G protein-coupled, seven-transmembrane 
(7TM) domain receptors (3). None of the cannabinoid 
receptor ligands, however, are entirely CB1- or CB2-specific. 
Each of these ligands therefore differs in effect, not only 
because they have different potency at cannabinoid 
receptors but also because they can interact with other non-
CB1/non-CB2 targets, such as transient receptor potential 
channel, vanilloid subfamily member 1 (TRPV1, aka 
capsaicin or vanilloid receptor), G protein-coupled receptors 
(GPR55 and GPR119), voltage-gated ion channels, and 
neuronal transporters of catecholamines (4–6). Despite such 
diversity, there are only four cannabinoid-based medicines 
currently on the market: nabiximols (Sativex®), nabilone 
(Cesamet® or Canemes®), dronabinol (Marinol® or 
Syndros®), and cannabidiol (Epidiolex®) (7). Still being 
developed are selective synthetic cannabinoid receptor 
agonists, antagonists, and modulators, metabolism 
inhibitors [such as fatty acid amide hydrolase (FAAH) 
inhibitors] or inhibitors of endocannabinoid reuptake (8).
The aim of this review is to summarise what is known 
about acute and chronic cannabinoid toxicity, primarily 
based on animal and clinical studies of medicinal product 
safety (9). Particular attention will be paid to identifying 
future studies that could fill in current gaps in knowledge 
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and uncertainties surrounding the safety of exogenous 
cannabinoids. This review will discuss the toxicology of 
chemically defined, single compounds that are either 
synthetic, semisynthetic, or plant-derived. We will also 
discuss why the combination of THC with CBD has fewer 
adverse effects than THC alone.
What this review will not discuss is the toxicology of 
medicinal or recreational cannabis use or the health issues 
associated with contaminants in plant extracts obtained 
from uncontrolled sources.
CANNABINOID RECEPTORS
THC shares the ability of endocannabinoid ligands 
anandamide (AEA) and 2-arachidonoylglycerol to activate 
both the CB1 and CB2 receptor. It is their partial agonist, as 
it binds to them with Ki values in the low nanomolar range. 
Both receptors are coupled through Gi/o proteins, negatively 
to adenylate cyclase and positively to mitogen-activated 
protein kinase (3). CB1 receptors are mainly located at the 
terminals of central and peripheral neurons, where they 
usually mediate inhibition of neurotransmitter release. CB1 
is one of the G protein-coupled receptors expressed at the 
highest level in the central nervous system, with the notable 
exception of the brain stem (4, 10). This may be why THC 
is not associated with sudden death due to respiratory 
depression, which indicates its low acute toxicity. In the 
brain, CB1 receptors are particularly concentrated in the 
hippocampus and cerebral cortex (areas involved in memory 
and cognition), olfactory areas, basal ganglia and cerebellum 
(areas involved in motor activity and posture control), 
hypothalamus (area involved in appetite regulation and 
energy homeostasis), limbic cortex (area involved in 
sedation), and neocortex (area involved in the executive 
function). CB1 is also found in peripheral nervous organs 
(lungs, liver, bowel, thyroid, uterus, placenta, and testicles). 
Therefore, these sites can also be the targets of cannabinoid 
effects. CB2 receptors are primarily associated with cells 
governing the immune function, such as splenocytes, 
macrophages, monocytes, microglia, and B- and T-cells. 
Recently, CB2 receptors have also been reported in other 
cells, often up-regulated under pathological conditions (5). 
The functions of these receptors include modulation of 
cytokine release and immune cell migration. CB2 receptors 
are expressed in the brain by microglia, blood vessels, and 
by some neurons (4, 10). However, their action has not been 
elucidated.
In contrast to THC, CBD does not seem to be 
psychoactive and has low affinity for CB1 and CB2 receptors 
(4). This is why its research has focused on non-CB1/non-
CB2 targets (see THC/CBD interactions below). When 
interpreting the effects of cannabinoids, we should bear in 
mind that cannabinoid receptors are members of the 
rhodopsin-like family of 7TM receptors, at which, 
according to Kenakin (11), the efficacy of agonist depends 
on cell type and its condition. Therefore, it is difficult to 
predict the therapeutic behaviour of cannabinoid receptor 
agonists. This is probably why higher release of 
endocannabinoids can be protective in one and damaging 
in another case.
TOXICOLOGICAL PROPERTIES OF THC
Apart from natural THC, the most reliable toxicological 
data available to date are for synthetic THC dronabinol and 
synthetic THC analogue nabilone. Nabilone has a similar 
chemical structure and is twice as potent as THC at the CB1 
and CB2 receptors (12). The main indication for dronabinol 
and nabilone is nausea and vomiting in adult patients 
receiving chemotherapy when conventional antiemetics fail 
to do the job. Dronabinol is also indicated for anorexia in 
adults with AIDS. There are no safety profiles for dronabinol 
and nabilone in paediatric (<18 years) and elderly (>65 
years) populations. The starting dose of dronabinol is 
2.5 mg, administered twice daily as capsules for oral use. 
The maximum recommended dosage is 20 mg/day (4–6 
doses a day). Dronabinol is also administered as a 5 mg/
mL oral solution. The usual nabilone dose is 1 or 2 mg twice 
a day, and the maximum recommended dosage is 6 mg/day, 
administered as capsules for oral use (13, 14). Since both 
are used short-term, data on chronic effects in humans are 
not available.
Pharmacokinetics/toxicokinetics of THC
The bioavailability of dronabinol is low (4–20 %) 
because of its high lipid solubility and extensive first-pass 
hepatic metabolism (15, 16). Its effects do not show clear 
dose dependence (17). Due to lipid solubility, the apparent 
volume of distribution is high (10 L/kg). Dronabinol is 
extensively metabolised in the liver, primarily by 
cytochrome P450 enzymes CYP2C9 and CYP3A4. 
CYP2C9 is probably responsible for the formation of the 
p r imary  ac t ive  me tabo l i t e  hydroxy-Δ 9-THC. 
Pharmacogenomics studies indicate two to three times 
higher plasma THC in individuals with a less active form 
of CYP2C9, so adverse drug reaction in these individuals 
may be more frequent and/or severe. The major route of 
excretion is faeces (65 %), and the minor is urine (20 %) 
(16). Urinary metabolites of dronabinol are identical to 
those of marijuana and may be excreted over long time (18).
Nabilone has better bioavailability (at least 60 %) than 
dronabinol and demonstrates dose linearity (15, 19). 
Multiple cytochrome P450 enzymes extensively metabolise 
nabilone to various metabolites, which have not been fully 
characterised yet. Two major metabolic pathways are 
probably involved in the biotransformation of nabilone: 1) 
enzymatic reduction of the 9-keto group to form carbinol 
metabolites; and 2) direct enzymatic oxidation of the 
aliphatic side-chain to produce carboxylic and hydroxylic 
analogues. The formation of carbinol metabolites is a major 
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nabilone metabolic pathway in dog. Hydroxylic analogues 
appear to be more important in rhesus monkey and man. 
Carbinols are long-lived metabolites that accumulate in the 
plasma and concentrate in the brains of treated dogs over 
time (see chronic toxicity) (20). Nabilone and its metabolites 
are primarily eliminated in faeces (~65 %) and to a lesser 
extent in urine (~20 %) (14, 17). Although no accumulation 
of nabilone was observed after repeated doses, some 
accumulation was observed for its metabolites (21).
Non-clinical toxicity of THC
Acute oral toxicity of THC in rats is lower in males 
(LD50=1910 mg/kg) than in females (LD50=1040 mg/kg) 
(22). The LD50 of oral nabilone is >1000 mg/kg in rats of 
both sexes (21). The signs of acute toxicity of THC and 
nabilone are similar and include lower respiratory rate, 
ataxia, decreased activity, catatonia, hypothermia, 
hypersensitivity to touch, and generalised body twitching. 
Death was reported to be due to respiratory arrest (21, 22).
Sub-chronic and chronic effects of THC (5, 15, 50, 150, 
and 500 mg/kg/day) administered by gavage were assessed 
in rats in a 13-week study followed by a 9-week recovery 
period and in a 2-year study (12.5, 25, and 50 mg/kg/day)
(23). Briefly, THC-treated rats had lower body weight than 
controls and exhibited convulsions, hyperactivity, and 
changes in the reproductive organs of both male and female 
rats. Reduced body weight was notable even at low dose 
exposure and was attributed to metabolic changes caused 
by THC. Weight loss was not associated with lower feed 
consumption but with increased energy consumption 
(evidenced by higher plasma corticosterone levels) needed 
for hyperactivity, adaptation, and detoxification from THC. 
Convulsions and hyperactivity were observed at all doses. 
The onset and frequency of convulsions were also dose-
related. However, Chan et al. (23) observed no histological 
changes in brain tissue of rats with a history of THC-related 
convulsion or seizures. Luthra et al. (24) reported 
generalised depression, followed by hyperactivity, 
irritability, aggressiveness, and convulsion in rats treated 
with THC for 119 days. The highest dose of THC in a sub-
chronic study in rats induced testicular atrophy and uterine 
and ovarian hypoplasia (23). This study also found higher 
serum FSH and LH at all doses.
Nabilone was assessed in two chronic toxicity studies 
(21). The one in beagle dogs (0.5, 1.0, 2.0 mg/kg/day) was 
planned to last one year but was terminated after seven 
months due to high mortality. Most deaths were preceded 
by convulsions, and toxicity was attributed to accumulation 
of carbinol metabolites in the brain over time. In contrast 
to dogs, nabilone chronic toxicity was minimal in rhesus 
monkeys receiving doses of up to 2.0 mg/kg/day for one 
year. Transient periods of anorexia, emesis, and ataxia were 
observed only at the highest dose.
Chan et al. (23) also evaluated THC carcinogenicity in 
rats and mice and found no evidence in rats at doses of up 
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to 50 mg/kg/day [~20 times the maximal human 
recommended dose (MHRD)]. In mice, THC produced 
thyroid follicular cell adenoma (a common benign neoplasm 
of the thyroid) in both sexes, but the effect was not dose-
dependent, as the hyperplasia was increased compared to 
control at all doses and in both sexes. It is unclear what 
these findings mean. Carcinogenicity studies have not been 
performed with nabilone.
Genotoxicity
THC and nabilone have no mutagenic potential (11–13, 
23). Positive Ames and skin test results in mice for THC in 
some in vitro tests are attributed to cytotoxic rather than 
mutagenic action (25).
Reproductive toxicity
THC was evaluated in an oral embryo-foetal 
developmental study in rats (at doses ranging from 12.5 to 
50 mg/kg/day) (26) and in rabbits (0.5, 1.5, 5 and 15 mg/
kg/day) (27). No teratogenic effects were observed in rats. 
Increased foetal mortality and early resorption were 
associated with maternal toxicity, which manifested itself 
as lower weight gain. In rabbits, one third of the foetuses 
in the high-dose group had multiple anomalies (such as 
acrania and spina bifida). In a single-generation reproductive 
study (28), male and female rats received 0.5, 1.5, and 5 mg/
kg/day of THC by gavage. Offspring to mothers receiving 
1.5 and 5 mg/kg/day showed a dose-related drop in survival 
at day 12 of lactation and at weaning.
A reproduction study of nabilone in rats (1.4, and 12 mg/
kg/day) and rabbits (0.7, 1.6, and 3.3 mg/kg/day) (29) 
showed no teratogenic effects. However, it did find dose-
related developmental toxicity, such as embryo death, foetal 
resorption, decreased foetal weight, and disrupted 
pregnancy. Another study in rats (24) revealed postnatal 
developmental toxicity of nabilone at 1.4 and 12 mg/kg/
day), manifested by smaller litter size and lower survival 
as well as lower initial body weight and hypothermia in 
pups from the high-dose group.
There are no sufficient data on pregnancy outcomes in 
women exposed to dronabinol (THC) or nabilone.
THC toxicity in clinical trials
Safety data on dronabinol come from 10 randomised, 
double-blind, placebo-controlled clinical trials. In one trial 
(30) patients with AIDS-related anorexia (N=139) were 
receiving dronabinol as appetite stimulant (5 mg/day), and 
in nine trials patients with cancer (N=454) were receiving 
dronabinol as antiemetic in the dose range of 2.5–40 mg/
day (31–39) for no longer than six weeks. The most 
frequently reported adverse events (33 %) in patients with 
AIDS were euphoria, dizziness, somnolence, and thinking 
abnormalities. The most common adverse events in patients 
receiving the antiemetic dronabinol were drowsiness, 
dizziness and transient impairment of sensory and 
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perceptual functions. Patients from both studies (24% in 
antiemetic and 8% in appetite stimulant) reported dose-
related “highs” (elation, laughter, and heightened 
awareness). The frequency of adverse effects on the central 
nervous system (CNS) increased with doses, and their 
severity greatly varied between patients. After oral 
administration, dronabinol had an action onset of 
approximately 30 min to one hour and a peak effect at two 
to four hours (40). Psychoactive effects lasted four to six 
hours. Other than those affecting the nervous system, the 
most frequent adverse effects were gastrointestinal 
(abdominal pain, nausea, and vomiting) and cardiovascular 
(palpitation, tachycardia, vasodilatation/facial flush) (30–
39). The following were the most serious adverse effects 
of dronabinol: neuropsychiatric, haemodynamic instability, 
seizure, paradoxical nausea, vomiting, and abdominal pain. 
Dronabinol should be discontinued in patients experiencing 
a psychotic reaction or showing cardiovascular effects 
(tachycardia, transient changes in blood pressure) and used 
with caution in patients with a history of epilepsy or 
recurrent seizures (13).
Nabilone has systematically been evaluated in 
controlled clinical trials that lasted up to nine weeks (41–
43). The lowest nabilone dose (2 mg) had a few adverse 
effects, whereas a 3–5 mg dose closely mirrored dronabinol’s 
(25 mg) effects (18).
THC addiction and dependence
High levels of CB1 receptors are found in the brain areas 
that are part of the mesocorticolimbic dopaminergic 
pathway and are implicated in motivational and reward 
processes (44). Being partial CB1 receptor agonists, THC 
and its analogues should be tested for their addictive 
potential (45). Many abused drugs that can lead to addiction 
increase synaptic dopamine levels in the human limbic 
striatum. The same was reported for THC in human studies 
in healthy participants (46–48). Dopamine release was small 
compared to amphetamine, cocaine, alcohol (10–15 %), 
and nicotine (~10 %).
First studies in monkeys (49, 50) failed to show the 
rewarding effects of THC, but newer studies with 
intravenous dronabinol injection (1–6 µg/kg) confirmed it 
in squirrel monkeys (51, 52). Another widely used predictor 
of a reinforcing (and therefore addictive) effect is the 
conditional place preference (CCP) test, in which a 
compartment in a cage is associated (paired) with a tested 
substance. Lepore et. al. (53) reported that CCP depended 
on the dose and intervals between administration and that 
dronabinol doses of 2 or 4 mg/kg every 24 h produced a 
reliable shift in favour of the dronabinol-paired compartment.
Reinforcing effects have also been observed in humans 
(12). Nabilone (4–8 mg/day) and dronabinol (10–20 mg/
day) produced stronger marijuana-like subjective effects, 
such as feeling good, feeling “high”, and feeling “stoned” 
than placebo. Nabilone had a slower onset of the peak 
subjective effects.
Chronic therapy with dronabinol can lead to physical 
dependence. One human study (17) showed that dronabinol 
doses of 210 mg/day (~10 times higher than MHRD) 
administered for 12 to 16 consecutive days produced 
withdrawal syndrome within 12 h after discontinuation. 
Initial symptoms were irritability, insomnia, and restlessness. 
By hour 24 of discontinuation, withdrawal symptoms 
intensified to include “hot flashes”, sweating, rhinorrhoea, 
loose stool, hiccoughs, and anorexia. We still do not know 
whether nabilone can also lead to physical dependence. 
Patients that participated in clinical trials for up to five days 
showed no withdrawal symptoms after discontinuation of 
dosing (54).
TOXICOLOGICAL PROPERTIES OF CBD
As a 99 % pure extract from C. sativa, active substance 
cannabidiol was first approved in June 2018 under 
proprietary name Epidiolex® (55). The United States Food 
and Drug Administration (US FDA) and European 
Medicines Agency (EMA) approved it for the treatment of 
seizures associated with Lennox-Gestaut (LGS) and Dravet 
syndrome (DS) in patients two years of age or older. 
Epidiolex® is administered as a 100 mg/mL oral solution. 
The starting dose is 2.5 mg/kg twice a day and the maximum 
recommended dose is 10 mg/kg twice a day (20 mg/kg/day) 
(55, 56). Considering that Epidiolex® has been approved 
for treatment in children, CBD has become the most 
extensively toxicologically tested cannabinoid, and thus the 
most reliable source of toxicological data. However, 
because of the seriousness of the indications and failure of 
patients to respond to existing medication, Epidiolex® was 
approved in spite of certain deficiencies in the safety 
assessment (e.g., inadequate safety assessment of major 
human metabolite 7-COOH-CBD). Additional studies listed 
in Table 1 should therefore be carried out as part of post-
marketing surveillance to obtain a complete safety profile 
of CBD. Furthermore, no clinical trial with Epidiolex® has 
been conducted in patients older than 55 years, so its safety 
profile does not cover the elderly population. General 
recommendation is to start with the lowest dose (56).
Since CBD is derived from C. sativa, Table 2 presents 
a thorough assessment of the abuse and dependence 
potential of Epidiolex® (4, 57–59). A human study (58) 
found marginal abuse potential at a higher therapeutic dose 
(1500 mg/day) and supratherapeutic dose (4500 mg/day), 
but there is little other evidence that CBD could cause 
addiction. The results of a human dependence study of CBD 
were negative (59).
Pharmacokinetics/toxicokinetics of CBD
Plasma CBD concentrations show a nonlinear increase 
with dose and 6.5 % bioavailability at a 3000-mg dose (60). 
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CBD absorption increases three times with a high-fat meal 
and six times with new oral delivery system for lipophilic 
active compounds (61, 62). Its high estimated volume of 
distribution (18,800—30,959 L) indicates accumulation of 
CBD in body fat (63). CBD is extensively metabolised in 
the liver and gut, mainly by the CYP2C19, CYP3A4, 
UGT1A7, UGT1A9, and UGT2B7 enzymes (64). Drug 
interaction trials to assess the effect of CBD on these 
enzymes in healthy volunteers will be conducted during the 
post-marketing period (Table 1) (55, 56). The metabolism 
of CBD is very complex, especially in hepatocytes. The 
main human metabolite is 7-carboxy-cannabidiol (7-COOH-
CBD; ~90 % of all drug-related substances measured in the 
plasma) (64). Its toxicological profile has not been 
investigated because experimental animals for toxicological 
studies (mice, rats, and dogs) do not metabolise CBD to a 
comparable extent as humans (65). The major concern with 
7-COOH-CBD could be its reactive acyl-glucuronide (66) 
The primary excretion route of CBD is through faeces 
(84 %), followed by urine (8 %) (63).
Non-clinical toxicology of CBD
In a study of acute effects in rhesus monkeys (67), 
intravenous CBD caused death by respiratory arrest and 
cardiac failure at doses above 200 mg/kg (LD50=212 mg/
kg). At the lower dose of 150 mg/kg, survivors recovered 
in one to three days, and liver weights increased from 19 
to 142 %. In the part of the study investigating subchronic 
effects (after 90 days of oral administration), the authors 
reported inhibition of spermatogenesis at the highest oral 
dose of 300 mg/kg (67).
Animal studies of CBD alone described below make 
part of the Epidiolex® European Public Assessment Report 
(EPAR, EMA’s scientific monography) (56). To the best of 
my knowledge, they have not been published and therefore 
no further detail or original references are currently 
available. All these studies were conducted in accordance 
with medicinal product safety standards and protocols and 
reviewed by the EMA committee (9).
Two oral chronic toxicity studies (referred to in 56) have 
assessed CBD in Wistar rats (receiving 15, 50, or 150 mg/
kg/day for 6 months) and Beagle dogs (receiving 10, 50, 
100 mg/kg/day for 9 months). In both species the primary 
target organ was the liver. Hepatocellular hypertrophy was 
detected at all doses, accompanied by an increase in alanine 
transferase (ALT) and alkaline phosphatase (ALP).
A 104-week oral carcinogenicity study in Wistar rats 
(referred to in 56) revealed no drug-related neoplastic 
findings. However, the study had several drawbacks, 
including impure active substance, excessive effect of body 
weight, and unknown exposure to the two major human 
metabolites.
Table 1 Recommended post-marketing studies to obtain a complete safety profile of cannabidiol (CBD)
Non-clinical toxicity studies
Toxicity studies with CBD metabolite 7-COOH-cannabidiol in rat:
- embryo-foetal developmental study 
- pre- and postnatal developmental study
- juvenile animal toxicity study 
- 2-year carcinogenicity study with gavage
Toxicity studies with CBD
- 2-year carcinogenicity study in mouse 
- 2-year carcinogenicity study in rat with gavage
Clinical studies
- Potential for chronic liver injury
- Effect on glomerular filtration rate
- Pregnancy outcome study
- QT interval prolongation trial at the maximum tolerable dose
Drug-drug interaction trials in healthy volunteers
CBD effect on the pharmacokinetics of: 
- caffeine 
- sensitive CYP2B6* and CYP2C9 substrate
- sensitive UGP1A9** and UGTB7 substrate
Strong CYP3A inhibitor effects on pharmacokinetics of CBD
Strong 2C9 inhibitor effects on pharmacokinetics of CBD
Rifampin effects on pharmacokinetics of CBD
* cytochrome P450; ** UDP-glucuronosyltransferase
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The genotoxic potential of CBD was also investigated 
in a standard battery of tests, but their results were negative 
for mutagenicity and clastogenicity (referred to in 56).
A full battery of oral reproductive and developmental 
studies has been conducted with purified CBD. In an 
embryo-foetal development study in Wistar rats, litter loss 
was noted at the highest applied dose of 250 mg/kg. In a 
prenatal and postnatal development study (referred to in 
56) rat exposure to the highest doses (150 and 200 mg/kg/
day) affected reproductive organs (smaller testes in males, 
reduced fertility index in females). A high dose of 125 mg/
kg also reduced foetal body weight in New Zealand white 
rabbit, which was related to maternal toxicity. The 
developmental toxicity in rabbits occurred at maternal 
plasma concentration similar to human at therapeutic doses 
(referred to in 56). In rats these concentrations were much 
higher. No adequate data are available on pregnancy 
outcome in women exposed to CBD.
A juvenile toxicity study in Wistar rats (referred to in 
56) showed neurobehavioral deficits and delayed sexual 
maturation in males. A no observed effect level (NOAEL) 
was 150 mg/kg/day.
Clinical toxicology of CBD
Safety data on Epidiolex® were obtained from four 
randomised, double-blind, placebo-controlled multicentre 
trials with exposure to CBD doses of 5, 10, and 20 mg/kg/
day (68–70). These phase II studies were conducted in 2 to 
55 year-old patients with LGS (N=235) and DS (N=88) for 
up to 14 weeks.
Additional non-controlled safety data have been 
obtained from an ongoing open-label Phase III study (Study 
1415) in LGS and DS patients (N=644), which is being 
conducted at 38 sites in the USA and Australia. Since this 
trial is not finished, an interim analysis of long-term safety 
was conducted (71, 72).
The most common adverse events in CBD-treated 
patients affected the following systems: CNS (somnolence, 
sedation), gastrointestinal tract (lower appetite, diarrhoea), 
liver (higher transaminase), and the lungs (pneumonia). The 
severity of these events was generally mild to moderate. 
Diarrhoea, weight loss, higher ALT, and somnolence/
sedation/lethargy were all dose-related. There were two 
serious cases of transaminase elevation, two severe events 
with rash (one consistent with a hypersensitivity reaction) 
and three severe cases of appetite loss. The CBD-treated 
and the placebo group did not differ in the rate of respiratory 
failure. Children had lower weight, which was associated 
to a certain extent with appetite loss (68–71).
Treatment with CBD is clearly associated with an 
increased risk of hepatotoxicity (68–71). Higher doses of 
CBD and concomitant use of valproate increase the risk of 
transaminase elevation in patients. Two patients 
concomitantly treated with valproate experienced toxic 
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Table 2 Cannabidiol (CBD) abuse potential
TYPE OF STUDY RESULTS
Receptor binding studies
- cannabinoid receptors no significant affinity
- opioid receptors no significant affinity
Non-clinical studies evaluating general behaviour (similarity to THC)
- tetrad test no meaningful abuse related signal
- drug discrimination study no meaningful abuse related signal
- self-administration study no meaningful abuse related signal
Clinical studies evaluating efficacy and safety in patients with LGS* or DS*
- Phase I clinical study no euphoria or other abuse-related signals
- Phase II/III studies could not be evaluated***
Phase I human abuse potential (HAP) study (N=40, with 35 completers)
randomized, double blind, placebo-controlled trial
subjects: healthy recreational poly-drug users
positive control: THC (10, 30 mg), alprazolam (2 mg) 
negative control: placebo
mean DRUG LIKING SCORE 
lower therapeutic dose: 750 mg/day not significantly different
higher therapeutic dose: 1500 mg/day significantly different (very small increase)
supra-therapeutic dose: 4500 mg/day significantly different (very small increase)
Human physical dependence study following chronic administration
3 days after discontinuation no withdrawal signs and symptoms
*Lennox-Gastaut syndrome; **Dravet syndrome; ***concomitant use of other seizure drugs and limited capacity of patients
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hepatocellular  injury,  metabolic acidosis ,  and 
encephalopathy. There appears to be no pharmacokinetic 
interaction between CBD and valproate, although a 
pharmacodynamical interaction is currently being 
investigated. The potential of CBD to cause chronic liver 
injury should be evaluated in the post-marketing period (55, 
56) (Table 1).
MECHANISMS OF THC/CBD 
INTERACTIONS
In spite of its low affinity for the CB1 and CB2 receptors, 
CBD can interfere with some THC adverse effects, 
particularly in the brain, without interfering with the 
intended THC effects, such as muscle relaxation (73). 
Understanding pharmacodynamic interactions between 
THC and CBD can be quite a challenge. CBD is a ligand 
with very low affinity for the CB1 receptor but can still 
increase CB1 constitutional or endocannabinoid activity (5), 
which has been confirmed by. thermodynamic findings that 
CBD increases membrane fluidity and thereby the activity 
of the CB1 receptor (74). Another mechanism of action is 
that CBD increases the levels of primary endocannabinoids 
AEA and 2-arachidonyl-glycerol (2-AG) (5). CBD may 
also interfere with THC through interaction with other non-
CB 1 receptors  and enzymes in  the ‘expanded 
endocannabinoid system’ (5). In their systematic review 
McPartland et al. (5) propose several non-CB1 receptor 
mechanisms of CBD antagonising or potentiating THC 
effects. For example, CBD may attenuate the anxiogenic 
effect of THC by acting as a direct or indirect agonist on 
serotonin 1A receptors (5-HT1A). In contrast, it can 
potentiate THC action on CB1 receptors by reducing 
peripheral hyperalgesia via TRPV1 channels (75). Sativex®, 
as a mixture of THC and CBD, consequently provided better 
antinociception than THC given on its own 76).
In terms of pharmacokinetic CBD/THC interaction, 
CBD may impair THC hydrolysis by CYP450 enzymes 
(77). The inhibition of THC metabolism may vary with 
species, timing of administration (CBD pre-administration 
vs co-administration), and CYP isoenzymes. In rats or mice 
THC effects are potentiated when CBD is administered 
30 min to 24 h before THC but mitigated if co-administered 
(78). In humans, no pharmacokinetic interactions between 
THC and CBD at clinically relevant doses have been 
reported (79). Co-administration of CBD with THC in one 
study (80) yielded similar maximum plasma levels of THC 
as when it was administered alone. Whether CBD will 
antagonise or potentiate THC effects also seems to depend 
on their administration ratio, and this ratio varies with 
species (5).
TOXICOLOGY OF CBD+THC 
COMBINATIONS
The combination of THC and CBD in a 1:1 ratio makes 
the active substance nabiximols of the cannabinoid-based 
medicine Sativex® (81). It is an oromucosal spray approved 
for the treatment of multiple sclerosis-associated spasticity 
in adult patients when all other treatment has failed. There 
is no safety profile of nabiximols in children (>18 years) 
and the elderly, even though clinical trials included patients 
up to 90 years of age. Elderly patients may be more 
susceptible to some adverse effects in the CNS. The 
oromucosal (e.g. sub-lingual) route resolves the problem 
of variable bioavailability (typically 6 to 20 %) of orally 
administered cannabinoids due to first-pass metabolism. 
Each 100 µL spray contains 2.7 mg THC and 2.5 mg CBD. 
The starting dose is two sprays per day and the maximum 
dose is 10–12 sprays per day (corresponding to 32.4 mg 
THC and 30 mg CBD) (81).
A study using a rat model of Huntington’s disease 
showed that nabiximols can up-regulate CB1 gene 
expression (82). CBD increases the levels of the primary 
endocannabinoids AEA and 2-arachidonyl-glycerol (2-AG) 
(6).
The most common adverse effects of nabiximols in 
clinical trials conducted in patients with multiple sclerosis 
were dizziness, fatigue and gastrointestinal disorders (e.g. 
nausea, vomiting, diarrhoea) (82–92). These adverse effects 
and poor efficacy were the main reasons for some patients 
to discontinue therapy (88, 90). In patients with multiple 
sclerosis the risk of accidental injury may be increased (83, 
87, 92–94). There is little evidence of abuse (addiction) or 
dependence, and the risk of either to develop is small. 
However, trials to date have mainly used therapeutic doses, 
and it is possible that supratherapeutic doses could cause 
addiction and/or dependence (85, 87, 92–94).
CONCLUSION
In spite of uncertainties about the safety of cannabinoids, 
there are no doubts about the acute neurological and 
cardiovascular effects of THC. However, THC is not 
associated with sudden death due to respiratory depression 
as is the case with opioid analgesics. Long-term cognitive, 
psychological, and endocrine effects of THC are still being 
investigated.
As for CBD, it can be toxic to the liver and increases 
the risk of somnolence and sedation, but the most commonly 
observed adverse events in controlled clinical trials were 
mild to moderate. However, these clinical trials included a 
small number of subjects and some aspects require 
continued pharmacovigilance. Regardless of different views 
on the subject, cannabinoid-based medicines need to be 
assessed just as any other substance in terms of quality, 
efficacy, and safety.
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Toksikološke lastnosti kanabinoidov
Iz rastline Cannabis sativa L. so do sedaj izolirali že več kot 100 fitokanabinoidov, poleg njih pa obstaja več kot 550 
sintetičnih spojin, ki delujejo na kanabinoidne receptorje CB1 in CB2. Prav tako je treba omeniti, da nobeden od ligandov 
kanabinoidnih receptorjev ni popolnoma CB1- ali CB2-specifičen. Zato se učinki vsakega od njih razlikujejo ne le zaradi 
različne moči na kanabinoidnih receptorjih, ampak tudi zato, ker lahko delujejo na druga ne-CB1 in ne-CB2 prijemališča. 
Najpogosteje proučevani kanabinoid je Δ9-tetrahidrokanabinol (THC). THC je delni agonist na obeh kanabinoidnih 
receptorjih, vendar je njegov psihoaktivni učinek povezan predvsem z aktivacijo receptorjev CB1. Receptor CB1 je eden 
izmed metabotropnih receptorjev z največjo ekspresijo v osrednjem živčevju, z izjemo možganskega debla. Čeprav so 
akutni učinki na osrednji živčni sistem THC jasno opredeljeni, je tveganje za ireverzibilne nevropsihološke učinke THC 
kot neodvisnega dejavnika potrebno nadalje raziskati za pojasnitev povezave. Za razliko od THC, fitokanabinoid kanabidiol 
(CBD) nima psihoaktivnih učinkov, vendar lahko pri sočasni uporabi vpliva na nekatere učinke THC. CBD, ki nima 
pomembne afinitete za CB1 in CB2, aktivira ali zavira številne uveljavljene in domnevne farmakološke tarče. CBD je kot 
aktivna snov v zdravilu Epidiolex® pred kratkim opravil nadzorovana klinična preskušanja, da so ocenili njegovo varnost 
pri zdravljenju redkih epileptičnih sindromov pri otrocih. Največjo zaskrbljenost glede varnosti so predstavljale povišane 
vrednosti transaminaz. Zato je treba izvesti postmarketinški nadzor toksičnosti za jetra. Članek bo povzel kar je znano o 
akutnih in kroničnih toksikoloških učinkih, katere študije še manjkajo in kaj so negotovosti v zvezi z varnostjo eksogenih 
kanabinoidov.
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